Aflunov Suspension for Injection 0.5ml in Pre-filled syringe

INJECTION, SUSPENSION

**4.2 Posology and method of administration** Posology: Adults and elderly (18 years of age and above): Individuals 18 years and older: Two 0.5 mL doses administered with an interval of at least 21 days between doses. In the event of an officially declared influenza pandemic due to H5N1 virus, persons previously vaccinated with one or two doses of AFLUNOV® that contained HA antigen derived from a different clade of the same influenza subtype as the pandemic influenza strain may receive a single dose of adjuvanted H5N1 pandemic vaccine instead of two doses that are required in previously unvaccinated individuals (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Paediatric population: There is limited experience in children between 6 months and 17 years of age (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Method of administration Immunisation should be carried out by intramuscular injection into the deltoid muscle.